Reason behind slow spread of nCoV in asia

-

Deficiency of specific protein which is common in USA and Europe than Asia, could explain why nCoV is not spreading faster in Asia.


A team of scientists from National Institute of Biomedical genomics in kalyani,west Bengal, have found a biological reason for slower spread of mutant coronavirus in Asia compared to west.



Team has explained how higher levels of human protein-neutrophil elastase, which helps virus to enter human cell, multiply and also spread faster from infected individuals.

NEUTROPHIL ELASATE:

Neutrophil elastase is serine protease, a major constituent of lung elastolytic activity. It potentially stimulates mucous secretion and induce CXCL6(Protein coding gene) release from epithelial cells.

However, this protein is kept in check by biological system, which provides another protein called alpha-1 antitrypsin(AAT)

AAT deficiency leads to higher level of neutophil elastase in the cells, which in turn helps in faster spread of the virus. This deficiency is known to be much higher in Europe and USA than Asia-as per article published in journal,infection,genetics and evolution.

The team of scientists led by Nidhan Biswas and Partha Majumder observed that the rate of the spread of the mutant virus — D614G — has been non-uniform across geographical regions.

The researchers say that, “…in order to reach 50% relative frequency, the 614G subtype took significantly longer time in East Asia (5.5 months) compared to Europe (2.15 months) as well as North-America (2.83 months).”

As per their data, AAT deficiency is the least in East Asian countries — 8 per 1,000 individuals in Malaysia, 5.4 per 1,000 in South Korea, 2.5 in Singapore. On the other hand, 67.3 in per 1,000 individuals in Spain are AAT deficient, 34.6 in the UK and 51.9 in France and in the US it is prevalent in 29 individuals among 1,000.

Comments

Post a Comment

Popular posts from this blog

Why plaque develop in artery, not in vein?

-
Image
  In medical community there is a group of clinicians who believe Low Density Lipoprotein (LDL) is major cause of atherosclerosis, while another group of clinicians believe LDL is not the cause of atherosclerosis. Confusing right? This article will provide insight on this ongoing debate in medical community. Argument proposed by clinicians who believe LDL is not the major cause of atherosclerosis: If LDL is causative risk factor for heart disease, why do we only see plaque in arteries not in vein? Seems legit point. Even if vein is part of same circulation, it receives same blood so it should have same exposure of LDL as to arteries. This is a great question. We are going to address this in this article.                                Figure: Comparison of structure of artery vs vein 1 Artery and vein have almost identical st...
Read more

Is corona virus human made?

-
Image
Corona virus Disease caused by SARS-CoV2 is originated from china. On 31st december,2019 china reported cluster of cases in Wuhan by unknown pathogen to WHO. American president Donald trump and many other representatives claimed that it was created in Wuhan center for disease control or Wuhan institute of virology. This news become more tricky when china did not allow WHO for investigation in laboratory. So what is the truth behind all this. Is really coronavirus human made? One article published in The Lancet journal shows that initially 27 cases out of 41 was linked to Wuhan wholesale seafood market. One way to find is coronavirus human made or naturally originated is comparing genome sequences. By decoding the genome sequence one can identify organoleptic characters in human like hair colour,eye colour and sex of human.So it can act similarly in case of virus. So decoding genome of virus is the best way to know its origin. Gene is made up of nucleotides. There are almost billion nuc...
Read more

Significant turn in india for COVID-19 treatment.

-
Image
Achievement of india in COVID-19. Drug major Glenmark Pharmaceuticals has become the first Indian company to commercially launch an antiviral drug for the treatment of mild to moderate COVID-19 patients after it received the Indian drug regulator Drug Controller General of India (DCGI) approval. The drug Favipiravir, under the brand name FabiFlu, will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said. Effectively, one tablet of FabiFlu would cost Rupees 103.  all you need to know about glenmark's COVID-19 treatment medicine: Glenmark is the first pharma firm to get approval for an oral drug to treat COVID-19 patients in India. Priced at Rs 3,500 for 34 tablets, the dosage is 200 mg X 9 tablets on day one and 200 mg X 4 tablets a day for 14 days. Global trials show the efficacy of over 80-88%; Japan, Bangladesh and UAE already use the drug for COVID-19 treatment. The drug will be available both throug...
Read more